(Press-News.org) (Phoenix Ariz. June 19, 2014) -- Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. In addition, this breakthrough showed a trend in improving survival although these data are not yet mature.
Trebananib (formally known as AMG 386; Amgen) is a first-in-class peptide-Fc fusion protein (or peptibody) that targets angiogenesis (the growth of new blood vessels into cancerous tumors) by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor. This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor (VEGF) such as bevacizumab (Avastin; Genentech).
Trebananib does not increase the risks of hypertension (high blood pressure) and bowel perforation like bevaciuzmab, but still has a similar impact on tumor shrinkage and delaying cancer progression.
Neither agent has shown a definitive increase in survival at this point.
TRINOVA-1 (Trebananib In Ovarian Cancer – 1; ClinicalTrials.gov, NCT01204749) was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.
The trial was run by Professor Bradley J. Monk MD who directs the Division of Gynecologic Oncology at the University of Arizona Cancer Center at St. Joseph's in Phoenix and sponsored by Amgen. Dr. Monk's site also was the largest enrolling site in Arizona.
"This is an exciting new targeted medication in treating recurrent ovarian cancer. Recurrent ovarian cancer is almost always fatal and new treatments are desperately needed," said Dr. Monk. "TRINOVA-1 also showed that angiogenesis is a complex process in oncology and many new targets like angiopoietin 1/2 will allow us to more effectively inhibit the growth of new blood vessels that are necessary for cancer growth, metastases and progression. If we can stop cancers from growing by choking off their blood supply, we can help our patients feel better and live longer."
Amgen, the manufacturer of trebananib has not yet filed this agent with the US Food and Drug Administration (FDA) but has also enrolled two other ovarian cancer phase III trials that have not yet had reported results (TRINOVA-2 [NCT01281254], and TRINOVA-3 [NCT01493505]).
TRINOVA-2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA-3, also known as ENGOT -Ov2 and Gynecologic Oncology Group - 3001, is studying the use of trebananib in front-line treatment adding it to carboplatin/paclitaxel. The results of these two additional trials are expected within a year and will hopefully add to a successful FDA application for approval making this agent available to American women with ovarian cancer.
The study will first be reported in the online editions of Lancet Oncology and then in the paper editions.
INFORMATION:
Researcher discovers ovarian cancer treatment
2014-06-20
ELSE PRESS RELEASES FROM THIS DATE:
Can we see the arrow of time?
2014-06-19
Einstein's theory of relativity envisions time as a spatial dimension, like height, width, and depth. But unlike those other dimensions, time seems to permit motion in only one direction: forward. This directional asymmetry — the "arrow of time" — is something of a conundrum for theoretical physics.
But is it something we can see?
An international group of computer scientists believes that the answer is yes. At the IEEE Conference on Computer Vision and Pattern Recognition this month, they'll present a new algorithm that can, with roughly 80 percent accuracy, determine ...
New driver of atherosclerosis offers potential as therapeutic target
2014-06-19
DALLAS – June 19, 2014 – A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target.
Atherosclerosis is characterized by the build-up of lesions (or plaques) formed from lipids, such as cholesterol and fatty acids. Ruptured plaques can partially or completely block blood flow, potentially leading to a heart attack or stroke. A member of a larger family of molecules ...
NASA's swift satellite tallies water production of Mars-bound comet
2014-06-19
In late May, NASA's Swift satellite imaged comet Siding Spring, which will brush astonishingly close to Mars later this year. These optical and ultraviolet observations are the first to reveal how rapidly the comet is producing water and allow astronomers to better estimate its size.
"Comet Siding Spring is making its first passage through the inner solar system and is experiencing its first strong heating from the sun," said lead researcher Dennis Bodewits, an astronomer at the University of Maryland College Park (UMCP). "These observations are part of a two-year-long ...
NASA's Hubble finds dwarf galaxies formed more than their fair share of universe's stars
2014-06-19
They may be little, but they pack a big star-forming punch. New observations from NASA's Hubble Space Telescope show small galaxies, also known as dwarf galaxies, are responsible for forming a large proportion of the universe's stars.
Studying this early epoch of the universe's history is critical to fully understanding how these stars formed and how galaxies grew and evolved 3.5 to 6 billion years after the beginning of the universe. The result supports a decade-long investigation into whether there is a link between a galaxy's mass and its star-forming activity, and ...
Georgia Tech research identifies Android security weaknesses caused by performance design
2014-06-19
Georgia Tech researchers have identified a weakness in one of Android's security features and will present their work at Black Hat USA 2014, which will be held August 6-7 in Las Vegas.
The research, titled Abusing Performance Optimization Weaknesses to Bypass ASLR, identifies an Android performance feature that weakens a software protection called Address Space Layout Randomization (ASLR), leaving software components vulnerable to attacks that bypass the protection. The work is aimed at helping security practitioners identify and understand the future direction of such ...
NASA and NAU researchers welcome unexpected asteroid findings
2014-06-19
What seemed to be rock-solid assumptions about the nature of small asteroids may end in collections of rubble or even a cloud of dust, but in such findings lies the lure of the unexpected.
Northern Arizona University researchers David Trilling and Michael Mommert, while playing a well-defined role in the NASA Asteroid Initiative, are beginning to wonder if they have found a separate path of investigation.
The two researchers presented their findings about asteroid 2011 MD on Thursday during a NASA event updating progress on the path to capturing a small asteroid and ...
A new tool to confront lung cancer
2014-06-19
Only 15% of patients with squamous cell lung cancer – the second most common lung cancer – survive five years past diagnosis. Little is understood about how the deadly disease arises, preventing development of targeted therapies that could serve as a second line of defense once standard chemotherapy regimens fail.
Published online in Cell Reports on June 19, Huntsman Cancer Institute investigators report that misregulation of two genes, sox2 and lkb1, drives squamous cell lung cancer in mice. The discovery uncovers new treatment strategies, and provides a clinically relevant ...
A better imager for identifying tumors
2014-06-19
WASHINGTON, June 19, 2014—Before they excise a tumor, surgeons need to determine exactly where the cancerous cells lie. Now, research published today in The Optical Society's (OSA) journal Optics Letters details a new technique that could give surgeons cheaper and more lightweight tools, such as goggles or hand-held devices, to identify tumors in real time in the operating room.
The new technology, developed by a team at the University of Arizona and Washington University in St. Louis, is a dual-mode imager that combines two systems—near-infrared fluorescent imaging to ...
Swiftly moving gas streamer eclipses supermassive black hole
2014-06-19
Astronomers have discovered strange and unexpected behaviour around the supermassive black hole at the heart of the galaxy NGC 5548. The international team of researchers detected a clumpy gas stream flowing quickly outwards and blocking 90 percent of the X-rays emitted by the black hole. This activity could provide insights into how supermassive black holes interact with their host galaxies.
The discovery of the unusual behaviour in NGC 5548 is the result of an intensive observing campaign using major ESA and NASA space observatories, including the NASA/ESA Hubble Space ...
LLNL, MIT researchers develop new ultralight, ultrastiff 3D printed materials
2014-06-19
LIVERMORE, Calif. – Imagine a material with the same weight and density as aerogel -- a material so light it's called 'frozen smoke' -- but with 10,000 times more stiffness. This material could have a profound impact on the aerospace and automotive industries as well as other applications where lightweight, high-stiffness and high-strength materials are needed.
Lawrence Livermore and Massachusetts Institute of Technology (MIT) researchers have developed a material with these properties using additive micro-manufacturing processes. The research team's findings are published ...